Tibet Duo Rui Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of chemical preparations, intermediates and active pharmaceutical ingredients. The Company mainly has self-produced products such as Sodium Acetate Ringer Injection and agent products such as Amoxicillin Sodium and Clavulanate Potassium for Injection. The Company's products mainly include liquid therapy, emergency medication, pediatric medication, psychiatric medication, and analgesic medication. The Company mainly operates its businesses in the domestic market.

Employees

461

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
09/07/26	CN¥63.40	+8.10%	2,565,041
09/07/26	CN¥58.65	-2.28%	2,049,284
08/07/26	CN¥60.02	-0.22%	1,549,700
07/07/26	CN¥60.15	+0.65%	1,468,900
06/07/26	CN¥59.76	+1.39%	2,100,725

End-of-day quote Shenzhen S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Shenzhen S.E. Other stock markets 10/07/2026			5-day change	1st Jan Change
63.40 ^CNY	+8.10%		+7.28%	+6.25%

04-28	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-23	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	5.01B 738M 646M 596M 550M 1.04B 70.41B 1.06B 7.12B 2.79B 34.69B 2.77B 2.71B 119B	P/E 2024	-22.7x	P/E 2025	-46.3x
Enterprise Value	5.33B 786M 688M 635M 586M 1.11B 75.01B 1.13B 7.58B 2.98B 36.95B 2.95B 2.89B 127B	EV / Sales 2024	6.46x	EV / Sales 2025	32.7x
Free-Float	30.57%	Yield 2024 *	-	Yield 2025	-

04-28	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-23	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-22	Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Hubei Hairuidi Pharmaceutical Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 2.4 million.	CI
04-22	Tibet Jiakang TImes Technology Development Co., Ltd. entered into an Equity Transfer Agreement to acquire 69% stake in Xiamen Ruitilian Pharmaceutical Technology Co., Ltd. from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 27.6 million.	CI
04-22	Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Wuhan Duorui Industrial Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 5.1 million.	CI
02-26	Wang Qingtai and Cao Xiaobing completed the acquisition of an additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd.	CI
02-24	Trading in Tibet Duo Rui Pharmaceutical's shares to halt	RE
01-20	Wang Qingtai and Cao Xiaobing proposed to acquire additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd. for approximately CNY 620 million.	CI
12-04	Wang Qingtai, Cui Zihao and Cao Xiaobing completed the acquisition of 29.99% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Zhoushan Qingchang Enterprise Management Partnership Enterprise (Limited Partnership) and Tibet Jiakang TImes Technology Development Co., Ltd.	CI
23/10/25	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
12/10/25	Wang Qingtai, Cui Zihao and Cao Xiaobing signed an share transfer agreement to acquire 29.99% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Zhoushan Qingchang Enterprise Management Partnership Enterprise (Limited Partnership) and Tibet Jiakang TImes Technology Development Co., Ltd. for approximately CNY 760 million.	CI
29/09/25	Duorui Pharma Expects Control Change Amid Parents' Plan	MT
29/09/25	Certain A Shares of Tibet Duo Rui Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 29-SEP-2025.	CI

1 day	+8.10%
1 week	+7.28%
Current month	+11.21%
1 month	-10.78%
3 months	+0.16%
6 months	+13.48%
Current year	+6.25%

Tibet Duo Rui Pharmaceutical Co., Ltd. Share Price

Stocks

301075

CNE100004RW5

Pharmaceuticals

Valuation: Tibet Duo Rui Pharmaceutical Co., Ltd.

Chart: Tibet Duo Rui Pharmaceutical Co., Ltd.

Latest news : Tibet Duo Rui Pharmaceutical Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Tibet Duo Rui Pharmaceutical Co., Ltd.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	55.81	64.66
1 month	54.89	71.29
Current year	54.89	98.29
1 year	30.51	98.29
3 years	12.6	98.29
5 years	12.6	98.29
10 years	12.6	98.29

Manager	Title	Age	Since
Yong Deng CEO	Chief Executive Officer	60	30/11/2018
Chao Li DFI	Director of Finance/CFO	47	30/04/2017
Fen Jin DFI	Director of Finance/CFO	46	30/11/2017

Director	Title	Age	Since
Ying Fei Liu BRD	Director/Board Member	48	20/02/2020
Yong Deng CHM	Chairman	60	30/11/2017
Shao Zhong Zhang BRD	Director/Board Member	70	20/02/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TIBET DUO RUI PHARMACEUTICAL CO., LTD.	+8.10%	+7.28%	+119.15%	+159.94%	681M
ELI LILLY AND COMPANY	-2.71%	-1.46%	+49.56%	+160.94%	1,085B
JOHNSON & JOHNSON	-0.84%	-1.23%	+62.44%	+60.59%	624B
ABBVIE INC.	-1.30%	-3.46%	+26.13%	+82.88%	442B
ROCHE HOLDING AG	+0.33%	-1.17%	+27.98%	+26.90%	332B
ASTRAZENECA PLC	-3.89%	-11.22%	+20.78%	+26.07%	277B
NOVARTIS AG	-0.02%	-2.85%	+25.27%	+44.88%	282B
NOVO NORDISK A/S	+0.66%	-1.42%	-29.26%	-39.30%	217B
AMGEN INC.	-0.40%	-1.15%	+20.59%	+61.18%	196B
GILEAD SCIENCES, INC.	-3.57%	+0.46%	+13.68%	+72.03%	167B
Average	-0.43%	-1.07%	+33.63%	+65.61%	362.26B
Weighted average by Cap.	-1.60%	-1.06%	+34.92%	+81.02%

	2024	2025
Net sales	241M 35.49M 31.04M 28.63M 26.44M 50.18M 3.38B 51.02M 342M 134M 1.67B 133M 130M 5.73B	154M 22.74M 19.89M 18.35M 16.94M 32.15M 2.17B 32.69M 219M 86.08M 1.07B 85.38M 83.52M 3.67B
Net income	-62.67M -9.24M -8.08M -7.46M -6.89M -13.07M -881M -13.29M -89.09M -34.99M -434M -34.7M -33.95M -1.49B	-102M -15.07M -13.18M -12.16M -11.23M -21.31M -1.44B -21.66M -145M -57.04M -708M -56.58M -55.35M -2.43B
Net Debt	135M 19.86M 17.38M 16.03M 14.8M 28.09M 1.89B 28.56M 191M 75.2M 933M 74.58M 72.96M 3.21B	327M 48.19M 42.15M 38.88M 35.91M 68.13M 4.6B 69.28M 465M 182M 2.26B 181M 177M 7.78B